Trade

with

Stemline Therapeutics Inc
(NASDAQ: STML)
AdChoices
14.16
+1.09
+8.34%
After Hours :
14.16
0.00
0.00%

Open

13.19

Previous Close

13.07

Volume (Avg)

103.24k (156.74k)

Day's Range

13.08-14.23

52Wk Range

10.50-33.55

Market Cap.

173.28M

Dividend Rate ( Yield )

-

Beta

-

Shares Outstanding

13.26M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 71.00k

    • Net Income

    • -24.20M

    • Market Cap.

    • 173.28M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -13,237.59

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • -

    • Forward P/E

    • -6.17

    • Price/Sales

    • 769.23

    • Price/Book Value

    • 2.60

    • Price/Cash flow

    • -6.87

      • EBITDA

      • -23.60M

      • Return on Capital %

      • -34.18

      • Return on Equity %

      • -36.12

      • Return on Assets %

      • -34.18

      • Book Value/Share

      • 5.04

      • Shares Outstanding

      • 13.26M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 62.00

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -2.12

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -13,237.59

            • 39.38

            • Net Profit Margin

            • -13,237.59

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 5.64

              • 2.92

              • Quick Ratio

              • 5.25

              • 2.35

              • Interest Coverage

              • -2,386.43

              • 38.02

              • Leverage Ratio

              • 1.07

              • 2.21

              • Book Value/Share

              • 5.04

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -5.80

                • 243.90

                • P/E Ratio 5-Year High

                • -21.35

                • 634.30

                • P/E Ratio 5-Year Low

                • -4.67

                • 124.82

                • Price/Sales Ratio

                • 769.23

                • 9.29

                • Price/Book Value

                • 2.55

                • 8.39

                • Price/Cash Flow Ratio

                • -6.87

                • 49.75

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -36.12

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -34.18

                    (-)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -36.11

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.00

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -23.98M
                  Operating Margin
                  -33,773.89
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -6.87
                  Ownership

                  Institutional Ownership

                  69.97%

                  Top 10 Institutions

                  53.41%

                  Mutual Fund Ownership

                  43.80%

                  Float

                  72.16%

                  5% / Insider Ownership

                  16.84%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    1,243,399

                  • 0.00

                  • 9.38

                  • Franklin Biotechnology Discovery

                  •  

                    808,130

                  • 70.37

                  • 6.11

                  • Eventide Gilead Fund

                  •  

                    435,500

                  • 47.68

                  • 3.28

                  • Janus Global Life Sciences Fund

                  •  

                    409,104

                  • 19.34

                  • 3.09

                  • Franklin Biotechnology Discovery Fund

                  •  

                    354,400

                  • 0.00

                  • 2.67

                  • Fidelity Advisor® Biotechnology Fund

                  •  

                    292,993

                  • 0.00

                  • 2.21

                  • Goldman Sachs Small/Mid Cap Growth Fund

                  •  

                    272,804

                  • -1.65

                  • 2.06

                  • Pru Ret Small Cap Growth/TimesSquare SP

                  •  

                    218,576

                  • -1.13

                  • 1.65

                  • AMG TimesSquare Small Cap Growth Fund

                  •  

                    204,774

                  • -1.54

                  • 1.54

                  • Vanguard Total Stock Mkt Idx

                  •  

                    179,382

                  • 0.00

                  • 1.35

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    1,640,892

                  • 0.00%

                  • 12.38

                  • Franklin Advisers, Inc.

                  •  

                    1,162,530

                  • +0.88%

                  • 8.77

                  • TimesSquare Capital Management, LLC

                  •  

                    798,025

                  • -1.61%

                  • 6.02

                  • Eventide Asset Management, LLC

                  •  

                    559,800

                  • +54.47%

                  • 4.22

                  • Ridgeback Capital Investments L.p.

                  •  

                    506,699

                  • -13.13%

                  • 3.87

                  • Janus Capital Management LLC

                  •  

                    495,384

                  • +15.45%

                  • 3.74

                  • SAC Capital Advisors, LP

                  •  

                    353,000

                  • +17.59%

                  • 2.67

                  • Baker Bros Advisors LLC

                  •  

                    338,671

                  • 0.00%

                  • 2.55

                  • Goldman Sachs Asset Management, L.P.

                  •  

                    301,902

                  • +41.28%

                  • 2.28

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  -

                  Stemline Therapeutics Inc was incorporated under the laws of the State of Delaware on August 8, 2003. The Company is a clinical-stage biopharmaceutical company engaged in discovering, acquiring, developing and commercializing proprie...moretary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk. It is developing two clinical-stage product candidates, SL-401 and SL-701. SL-401 is a targeted therapy directed to the interleukin-3 receptor, or IL-3R, present on CSCs and tumor bulk. SL-401 has demonstrated single-agent activity, including durable complete responses, or CRs, in investigator sponsored Phase 1/2 trials in several indications including blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and relapsed or refractory acute myeloid leukemia, or AML. SL-701 is a subcutaneously-a...moredministered therapeutic cancer vaccine comprised of multiple synthetic peptides. The vaccine has demonstrated single-agent activity, including durable CRs and partial responses, or PRs, in investigator sponsored Phase 1/2 trials in advanced adult and pediatric brain cancers. In addition, Company has built a preclinical pipeline which includes next generation IL-3R-targeted compounds SL-501 and SL-101 discovery platform, and an intellectual property portfolio including some of the earliest patents in the CSC area. Some of its competitors include Cyclacel Pharmaceuticals, Inc., Sunesis Pharmaceuticals Inc., Clavis Pharma ASA, Ambit Biosciences Corporation, Celgene Corporation, Merck & Co., Inc., Eisai Co., Inc. and Roche Holding AG. Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those it is developing.lessless

                  Key People

                  Dr. Ivan Bergstein

                  CEO/Chairman of the Board/Director/Founder/President

                  Dr. Eric K. Rowinsky,M.D.

                  Chief Medical Officer/Executive VP/Other Corporate Officer

                  Mr. David G. Gionco

                  Chief Accounting Officer/Vice President, Divisional

                  Eric L. Dobmeier

                  Director

                  Ron Bentsur

                  Director

                  • Stemline Therapeutics Inc

                  • 750 Lexington Avenue

                  • New York, NY 10022

                  • USA.Map

                  • Phone: +1 646 502-2311

                  • Fax: +1 646 389-0968

                  • stemline.com

                  Incorporated

                  2003

                  Employees

                  20

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: